ADAMTS14, ARHGAP22, and EPDR1 as potential novel targets in acute myeloid leukaemia

Omar S. El-Masry; Ali M. Alamri; Faisal Alzahrani; Khaldoon Alsamman

doi:10.1016/j.heliyon.2022.e09065

ADAMTS14, ARHGAP22, and EPDR1 as potential novel targets in acute myeloid leukaemia

Omar S. El-Masry
, Ali M. Alamri
, Faisal Alzahrani
, Khaldoon Alsamman^*

^*Corresponding author for this work

Clinical Laboratory Sciences Department

Imam Abdulrahman Bin Faisal University

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Acute myeloid leukaemia (AML) is a blood cancer with a heterogeneous genomic landscape. This study aimed to mine bioinformatics data generated by RNA sequencing to unveil an AML case transcriptome profile and identify novel therapeutic targets and markers. In this study, we have determined the transcriptomic profile and analysed gene variants of an AML patient at the time of diagnosis and validated some genes by quantitative reverse transcriptase polymerase chain reaction. ADAMTS14, ARHGAP22, and ependymin-related protein 1 (EPDR1) were markedly upregulated compared to the corresponding control. In addition, novel exonic single-nucleotide and insertion/deletion variants were identified in these genes. Hence, ADAMTS14, ARHGAP22, and EPDR1 can be proposed as potential novel targets in AML, and their exact roles should be further explored.

Original language	English
Article number	e09065
Journal	Heliyon
Volume	8
Issue number	3
DOIs	https://doi.org/10.1016/j.heliyon.2022.e09065
State	Published - Mar 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Acute myeloid leukaemia
ADAMTS14
ARHGAP22
EPDR1
Insertion/deletion
RNA sequencing
Single nucleotide polymorphism

Access to Document

10.1016/j.heliyon.2022.e09065

Cite this

@article{19dfa7f611934225806f49cf8a8717c6,

title = "ADAMTS14, ARHGAP22, and EPDR1 as potential novel targets in acute myeloid leukaemia",

abstract = "Acute myeloid leukaemia (AML) is a blood cancer with a heterogeneous genomic landscape. This study aimed to mine bioinformatics data generated by RNA sequencing to unveil an AML case transcriptome profile and identify novel therapeutic targets and markers. In this study, we have determined the transcriptomic profile and analysed gene variants of an AML patient at the time of diagnosis and validated some genes by quantitative reverse transcriptase polymerase chain reaction. ADAMTS14, ARHGAP22, and ependymin-related protein 1 (EPDR1) were markedly upregulated compared to the corresponding control. In addition, novel exonic single-nucleotide and insertion/deletion variants were identified in these genes. Hence, ADAMTS14, ARHGAP22, and EPDR1 can be proposed as potential novel targets in AML, and their exact roles should be further explored.",

keywords = "Acute myeloid leukaemia, ADAMTS14, ARHGAP22, EPDR1, Insertion/deletion, RNA sequencing, Single nucleotide polymorphism",

author = "El-Masry, \{Omar S.\} and Alamri, \{Ali M.\} and Faisal Alzahrani and Khaldoon Alsamman",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = mar,

doi = "10.1016/j.heliyon.2022.e09065",

language = "English",

volume = "8",

journal = "Heliyon",

issn = "2405-8440",

number = "3",

}

TY - JOUR

T1 - ADAMTS14, ARHGAP22, and EPDR1 as potential novel targets in acute myeloid leukaemia

AU - El-Masry, Omar S.

AU - Alamri, Ali M.

AU - Alzahrani, Faisal

AU - Alsamman, Khaldoon

PY - 2022/3

Y1 - 2022/3

N2 - Acute myeloid leukaemia (AML) is a blood cancer with a heterogeneous genomic landscape. This study aimed to mine bioinformatics data generated by RNA sequencing to unveil an AML case transcriptome profile and identify novel therapeutic targets and markers. In this study, we have determined the transcriptomic profile and analysed gene variants of an AML patient at the time of diagnosis and validated some genes by quantitative reverse transcriptase polymerase chain reaction. ADAMTS14, ARHGAP22, and ependymin-related protein 1 (EPDR1) were markedly upregulated compared to the corresponding control. In addition, novel exonic single-nucleotide and insertion/deletion variants were identified in these genes. Hence, ADAMTS14, ARHGAP22, and EPDR1 can be proposed as potential novel targets in AML, and their exact roles should be further explored.

AB - Acute myeloid leukaemia (AML) is a blood cancer with a heterogeneous genomic landscape. This study aimed to mine bioinformatics data generated by RNA sequencing to unveil an AML case transcriptome profile and identify novel therapeutic targets and markers. In this study, we have determined the transcriptomic profile and analysed gene variants of an AML patient at the time of diagnosis and validated some genes by quantitative reverse transcriptase polymerase chain reaction. ADAMTS14, ARHGAP22, and ependymin-related protein 1 (EPDR1) were markedly upregulated compared to the corresponding control. In addition, novel exonic single-nucleotide and insertion/deletion variants were identified in these genes. Hence, ADAMTS14, ARHGAP22, and EPDR1 can be proposed as potential novel targets in AML, and their exact roles should be further explored.

KW - Acute myeloid leukaemia

KW - ADAMTS14

KW - ARHGAP22

KW - EPDR1

KW - Insertion/deletion

KW - RNA sequencing

KW - Single nucleotide polymorphism

UR - https://www.scopus.com/pages/publications/85126105339

U2 - 10.1016/j.heliyon.2022.e09065

DO - 10.1016/j.heliyon.2022.e09065

M3 - Article

AN - SCOPUS:85126105339

SN - 2405-8440

VL - 8

JO - Heliyon

JF - Heliyon

IS - 3

M1 - e09065

ER -

ADAMTS14, ARHGAP22, and EPDR1 as potential novel targets in acute myeloid leukaemia

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this